Posted by Michael Wonder on 18 Nov 2020
Dupixent (dupilumab injection) now approved by Health Canada for patients with severe asthma
17 November 2020 - Only biologic approved in Canada to treat severe asthma with type 2 / eosinophilic phenotype, or oral corticosteroid-dependent asthma.
Sanofi Canada announced today that Health Canada approved a new indication for Dupixent (dupilumab), for adults and adolescents aged 12 years and older as an add-on maintenance treatment for severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.
